Announcement of Self-Inspection Report
Shanxi Panlong Pharmaceutical Group Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or major omissions.
On May 12, 2026, the Company held the seventh meeting of the fifth Board of Directors, which reviewed and approved the proposal on the "2026 Stock Option Incentive Plan (Draft)" and related proposals. The specific content can be found in the announcement disclosed on May 13, 2026, on the Giant Tide Information Network (http://www.cninfo.com.cn). The aforementioned proposals have been reviewed and approved by the Company's Board of Directors' Compensation and Assessment Committee.
In accordance with the "Management Measures for Equity Incentives of Listed Companies" (hereinafter referred to as "Management Measures"), "Management Measures for Information Disclosure of Listed Companies," and "Self-Regulatory Guidelines No. 1 for Business Handling of Listed Companies on the Shenzhen Stock Exchange" (hereinafter referred to as "Guidelines No. 1"), as well as relevant laws, regulations, departmental rules, normative documents, and the Company's "Information Disclosure Management System" and related internal confidentiality systems, the Company has taken sufficient and necessary confidentiality measures for the "2026 Stock Option Incentive Plan" (hereinafter referred to as "this Incentive Plan") and has registered the insiders of this Incentive Plan.